基线淀粉样蛋白沉积表型预测lecanemab早期清除的空间分布
本研究用SuStaIn模型在303人中识别Aβ沉积表型,并应用于39例接受lecanemab治疗患者基线与6个月Aβ-PET。基线Aβ表型不影响整体清除幅度,但预测区域清除的空间模式;基线沉积与早期清除存在定量空间对应。
要点
- 基线CL强烈预测ΔCL(r=-0.68,P<0.001),表型间ΔCL无差异。
- 基线拓扑预测区域清除模式:后部优势基线预示更大后部清除。
- ROI水平清除随基线区域SUVR增加(混合效应β=0.264,p<0.001)。
核心结论
- 基线Aβ表型不影响早期整体淀粉样蛋白清除幅度,但预测区域清除的空间模式。
- 基线沉积与早期清除的定量拓扑对应提供靶点 engagement 的体内证据,支持超越整体CL的拓扑信息PET监测。
研究设计与样本
- 用303人(249例Aβ+/tau+ PET确诊AD和54例Aβ-/tau-对照)的横断面Aβ-PET SUVR训练SuStaIn模型识别Aβ进展表型。
- 将训练模型应用于39例lecanemab治疗患者,配对基线及6个月Aβ-PET,量化整体CL和区域SUVR。
主要发现
- SuStaIn识别两种主要表型:枕叶起病模式(亚型1)和楔前叶-额叶起病模式(亚型2)。
- lecanemab队列平均ΔCL为-27.77±24.51,亚型1(n=16)与亚型2(n=17)间ΔCL无差异,基线CL强烈预测ΔCL(r=-0.68,P<0.001)。
- ROI水平ΔSUVR经FDR校正后差异不显著,但ΔSUVR与基线SUVR显著相关(r=-0.64,P<0.0001)。
- 在33例可分类患者中,后部优势基线拓扑预测更大后部清除;Topo_occ-fron变化与基线值相关(r=0.514,P<0.01),调整基线CL后仍显著(β=-0.273,P<0.01)。
- ROI水平清除幅度随基线区域SUVR增加(混合效应β=0.264,p<0.001)。
关键数值与推荐
- 基线CL预测ΔCL:r=-0.68,P<0.001。
- ΔSUVR与基线SUVR相关:r=-0.64,P<0.0001。
- Topo_occ-fron变化与基线值相关:r=0.514,P<0.01;调整基线CL后β=-0.273,P<0.01。
- ROI水平清除与基线SUVR混合效应:β=0.264,p<0.001。
临床怎么用
- lecanemab治疗早期整体Aβ清除幅度不受基线表型影响,但区域清除模式与基线沉积拓扑对应。
- 除整体CL外,可结合基线Aβ-PET拓扑信息进行PET监测,以评估区域靶点 engagement。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lecanemab effectively reduces brain amyloid-β (Aβ) burden in early Alzheimer's disease (AD). However, Aβ deposition is spatially heterogeneous.The aim of this study is to test whether baseline β-amyloid (Aβ) deposition phenotype influences lecanemab-related Aβ clearance on Aβ-PET. METHODS: An Aβ Subtype and Stage Inference (SuStaIn) model was trained to identify Aβ progression phenotypes using cross-sectional Aβ-PET SUVRs from seven brain regions in 303 individuals (249 Aβ+/tau + PET-confirmed Alzheimer's disease and 54 Aβ-/tau- controls). This trained model was then applied to 39 lecanemab-treated patients with paired baseline and 6‑month Aβ-PET. Global and regional Aβ burden was quantified in Centiloids (CL) and SUVR, respectively. Subtype differences in ΔCL and ΔSUVR were tested. By defining baseline topology and clearance topology using posterior-to-anterior dominance indices (Topo_occ-fron = SUVR of occipital lobe - SUVR of frontal lobe), topology-clearance coupling was assessed using correlation and regression analysis. Additionally, spatial topological correspondence was quantified by modeling ROI-level clearance as a function of ROI-level baseline SUVR within a mixed-effects model with a subject-level random intercept. RESULTS: SuStaIn identified two dominant phenotypes consistent with an occipital-onset pattern (subtype 1) and a precuneus-frontal-onset pattern (subtype 2). In the lecanemab cohort, CL decreased by a mean ΔCL of - 27.77 ± 24.51. ΔCL did not differ between subtype 1 (n = 16) and subtype 2 (n = 17), whereas baseline CL strongly predicted ΔCL (r = -0.68, P < 0.001). ROI-wise ΔSUVR differences were not significant after FDR correction, while the ΔSUVR was significantly correlated with baseline SUVR (r = -0.64, P < 0.0001). In subtype-assigned patients (n = 33), a posterior-dominant baseline topology predicted greater posterior clearance. The changed Topo_occ-fron is correlated with baseline values (r = 0.514, P < 0.01) and remained significant after adjusting for baseline CL (β=-0.273, P < 0.01). ROI-level clearance magnitude increased with baseline regional SUVR (mixed-effects β = 0.264, p < 0.001), quantifying high spatial correspondence between deposition and clearance. CONCLUSION: While baseline Aβ phenotype did not influence the magnitude of early global amyloid removal, it predicted the spatial pattern of regional clearance. Quantitative topological correspondence between baseline deposition and early clearance provides in vivo evidence of target engagement and supports topology-informed PET monitoring beyond global CL.
引用
- Dou X, Hu D, Wang J, et al. Baseline amyloid deposition phenotypes inform the spatial distribution of early amyloid clearance with lecanemab in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2026. PMID: 42297931. doi:10.1007/s00259-026-07989-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。